About NTCELL

NTCELL is an alginate-coated capsule product containing clusters of neonatal porcine choroid plexus (CP) cells. The capsules are implanted into the damaged site within the brain to target the treatment of Parkinson’s disease.

NTCELL is developed from a unique herd of designated pathogen-free pigs, bred from stock originally discovered in the remote sub-Antarctic Auckland Islands in New Zealand. Algorae maintains a dedicated pig herd and surgical facility in New Zealand for the manufacture of GMP-grade NTCELL.

Algorae Pharmaceuticals (formerly Living Cell Technologies) has commenced a scientific review of previous Phase 2 clinical trial data and the NTCELL clinical development plan, to assess and implement recommendations proposed by the NTCELL Scientific Advisory Board.

How NTCELL Works

Choroid plexus cells are naturally occurring support cells for the brain. They secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions, including protective enzymes crucial for nerve growth and healthy functioning.

In NTCELL, the porcine choroid plexus cells are coated with Algorae’s proprietary IMMUPEL™ technology to protect them from immune system attack — meaning no immunosuppressive regimen is required for treatment.

Following implantation, NTCELL functions as a neurochemical factory, producing CSF and secreting multiple nerve growth factors that promote new central nervous system growth and repair disease-induced nerve degeneration.

AI-116

Dementia

Stage: Preclinical  |  PCT Filed

Fixed-dose combination of CBD and donepezil. 53% cell viability vs 17% with donepezil alone in preclinical validation. PCT patent filed (PCT/AU2024/050791).

AI-168

Cardiovascular

Stage: Preclinical | PCT Filed

Fixed-dose combination cannabinoid candidate for cardiovascular disease. Preclinical data: 94% endothelial restoration, 80% smooth muscle normalisation.